Zenapax daclizumab: Marketed

Researchers reported 3-year follow-up data from two Phase III trials showing a combined 91 percent survival rate for patients who did not receive Zenapax compared to 94 percent for those who did.

In a separate study of 45 transplant recipients given Zenapax in conjunction with an immunosuppressive regimen that did not include cyclosporine, patient survival at 1 year was 100 percent and graft survival was 95 percent. At that time, 49 percent of patients did not require cyclosporine maintenance therapy. PDLI said that patients not on cyclosporine had improved renal function and easier-to-control high blood pressure than patients on cyclosporine. ...